Related Experiment Video
Updated: Feb 5, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report
C Lapucci1, F Gualandi2, M Mikulska3
1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy.
Background:
Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). The only report of Serum Sickness (SS) in a MS patient occurred during treatment with natalizumab. Non-protein drugs, such as some antibiotics, may induce "SS-like" reactions (SSLR), whose clinical and laboratory features may partially overlap with the traditional SS.
Objective:
To report a case of SS/SSLR in a RRMS patient treated with alemtuzumab.
Case Report:
A 42-year-old-woman with RRMS developed SS/SSLR in the first week after the first alemtuzumab treatment. Concomitant medications included trimethoprim-sulfamethoxazole at low dose. Intravenous methylprednisolone therapy led to clinical resolution and normalization of serum inflammatory markers.
Conclusion:
SS/SSLR should be considered in patients treated with alemtuzumab developing delayed fever, rash and arthralgia and differentiated with Infusion Associated Reactions (IARs) and infections.
Related Concept Videos
Data Reporting and Recording
Multiple Halogenation of Methyl Ketones: Haloform Reaction
Determining Order of Reaction
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Enthalpies of Reaction
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:

